TNF Pharmaceuticals, Inc. Common StockTNFA
About: TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
Employees: 2
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
142% more capital invested
Capital invested by funds: $60.3K [Q3] → $146K (+$85.6K) [Q4]
25% more funds holding
Funds holding: 20 [Q3] → 25 (+5) [Q4]
3.02% more ownership
Funds ownership: 1.57% [Q3] → 4.6% (+3.02%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TNFA.
Financial journalist opinion









